Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. $1801.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-36
RECRUITING5
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Picankibart NCT06945107 |
P3 | Active, not recruiting | Plaque Psoriasis | 308 | 2026-06-07 |
| IBI112 NCT07265284 |
P3 | Recruiting | Psoriasis | 104 | 2026-09-30 |
| Bevacizumab NCT07490262 |
P2/3 | Recruiting | Hepatocellular Carcinoma (HCC) | 680 | 2027-12-31 |
| Trastuzumab NCT07377643 |
P3 | Recruiting | HER2-positive Breast Cancer | 540 | 2028-04-28 |
| Picankibart NCT07295509 |
P2/3 | Recruiting | Psoriatic Arthritis | 222 | 2029-12-31 |
| tegafur, Gimeracil and Oteracil Potassium Capsules NCT07643623 |
P2/3 | Recruiting | Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | 720 | 2031-12-31 |